Abstract

Chemokine (C-C motif) receptor 5 (CCR5) is expressed not only in the immune cells but also in cerebral cells such as neurons, glia, and vascular cells. Stroke triggers high expression of CCR5 in the brain. However, the role of CCR5 in stroke remains unclear. In this study, using bone marrow chimeras we have determined the involvement of brain-derived or bone marrow-derived CCR5 in neuroprotection and brain repair after experimental stroke. CCR5-/- mice that received either wild-type (WT) or CCR5-/- bone marrow transplantation showed larger infarction sizes than the WT mice that received either WT or CCR5-/- bone marrow transplantation in both the acute (48h) and subacute (2 months) phases after cerebral cortical ischemia, suggesting that the lack of CCR5 in the brain leads to severe brain damage after stroke. However, the lack of CCR5 in the bone marrow-derived cells did not affect infarction size. The impairments of somatosensory-motor function and motor coordination were exacerbated in the mice lacking CCR5 in the brain. At 2 months post-stroke, increased degenerative neurons, decreased dendrites and synapses, decreased Iba1+ microglia/ macrophages, reduced myelination and CNPase+ oligodendrocytes in the peri-infarct cortex were observed in the mice lacking CCR5 in the brain. These pathological changes are significantly correlated with the increased infarction size and exacerbated neurological deficits. These data suggest that brain-derived CCR5 plays a key role in neuroprotection and brain repair in the subacute phase of stroke. This study reveals a novel role of CCR5 in stroke, which sheds new light on post-stroke pathomechanism.

Highlights

  • Chemokine (C-C motif) receptor 5 (CCR5) is expressed in the immune cells and in cerebral cells such as neurons, glia, and vascular cells

  • In this study we have identified the effects of brainderived chemokine receptor 5 (CCR5) or bone marrow-derived CCR5 on brain protection after cerebral cortical ischemia

  • Our data have revealed that after cerebral cortical ischemia: (1) Brainderived CCR5, not bone marrow-derived CCR5, mainly contributes to neuroprotection in both acute and subacute phases; (2) Brain-derived CCR5 deficiency plays the predominant role of exacerbating neurological deficits in the subacute phase; (3) Brain-derived CCR5 shows protective and reparative effects on reducing neural degeneration, modulating neuroinflammation and promoting myelination in the subacute phase; (4) The protective and reparative effects of brain-derived CCR5 are significantly associated with both Iba1 positive cells and oligodendrocytes in the peri-infarct cortex

Read more

Summary

Introduction

Chemokine (C-C motif) receptor 5 (CCR5) is expressed in the immune cells and in cerebral cells such as neurons, glia, and vascular cells. These pathological changes are significantly correlated with the increased infarction size and exacerbated neurological deficits These data suggest that brain-derived CCR5 plays a key role in neuroprotection and brain repair in the subacute phase of stroke. Genetic ablation of CCR5 (i.e., CCR5 knockout mice) results in the increase of infarction size and exacerbation of motor functional deficits after experimental stroke [22], demonstrating neuroprotective effects of CCR5 in ischemic brain injury. It remains unclear, whether CCR5 is needed for brain repair in the subacute phase. We have identified the effects of brain-derived CCR5 or bone marrow-derived CCR5 on neuroprotection in the acute and subacute phases and on brain repair in the subacute phase of experimental stroke

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call